Wall Street analyst estimates for ProQR Therapeutics N.V. (PRQR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10).
Analyst Consensus
| Strong Buy | 1 |
| Buy | 10 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.11 | ||
| 2026-08-13 | $-0.10 | $-0.13 | +23.2% |
| 2026-05-12 | $-0.15 | $-0.15 | +0.0% |
| 2026-03-12 | $-0.09 | $-0.08 | -12.5% |
| 2025-11-06 | $-0.12 | $-0.10 | -20.0% |
| 2025-08-07 | $-0.14 | $-0.08 | -75.0% |
| 2025-05-08 | $-0.11 | $-0.09 | -22.2% |
| 2025-03-13 | $-0.10 | $-0.10 | +0.0% |
Valuation Ratios
| Price / Book | 2.09 |
| EV / EBITDA | -2.27 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | -$1.5M | $4.9M | $1.9M | $1.0M | $1.3M | $3.6M | $6.5M | $18.9M | $15.3M |
| Cost of Revenue | $1.3M | $1.0M | $983511 | $116.8M | 0 | 0 | 0 | 0 | 0 | $2.6M |
| Gross Profit | $1.0M | -$2.5M | $4.0M | -$114.9M | $1.0M | $1.3M | $3.6M | $6.5M | $18.9M | $12.7M |
| Research & Development | $31.9M | $31.2M | $29.5M | $46.5M | $38.1M | $42.2M | $50.9M | $25.1M | $36.4M | $40.7M |
| Selling, General & Admin | $9.5M | $10.8M | $12.5M | $12.9M | $13.7M | $17.4M | $18.7M | $16.2M | $13.7M | $15.1M |
| Operating Expenses | $41.4M | $42.0M | $42.1M | $59.4M | $43.4M | $58.5M | $68.8M | $38.4M | $49.4M | $54.8M |
| Operating Income | -$39.6M | -$40.5M | -$36.3M | -$57.4M | -$42.4M | -$57.2M | -$65.2M | -$31.9M | -$30.5M | -$42.2M |
| EBITDA | -$120.5M | 0 | -$35.3M | -$174.3M | -$48.4M | -$54.9M | -$56.5M | -$24.1M | -$24.1M | -$37.0M |
| Interest Expense | $538000 | $596000 | $810000 | $1.1M | $2.0M | $3.4M | $5.1M | $1.2M | $1.1M | $866400 |
| Pre-tax Income | -$39.1M | -$43.7M | -$37.1M | -$56.6M | -$46.5M | -$60.7M | -$64.1M | -$27.8M | -$28.0M | -$40.5M |
| Income Tax | 0 | $2000 | $1000 | $132000 | $124000 | $117000 | $96000 | -$78000 | -$197000 | $18249 |
| Net Income | -$39.1M | -$43.6M | -$36.9M | -$56.7M | -$46.6M | -$60.7M | -$64.4M | -$28.1M | -$27.8M | -$40.5M |
| EPS | $-1.67 | $-1.72 | $-1.08 | $-1.38 | $-0.93 | $-0.96 | $-0.91 | $-0.35 | $-0.34 | $-0.38 |
| EPS (Diluted) | $-1.67 | $-1.72 | $-1.08 | $-1.38 | $-0.93 | $-0.96 | $-0.91 | $-0.35 | $-0.34 | $-0.38 |
| Shares Outstanding (Diluted) | $23.3M | $25.4M | $34.1M | $41.0M | $50.1M | $64.2M | $71.6M | $81.0M | $81.7M | $105.3M |
Price
| Price | $1.86 |
| Market Cap | $196M |
| Exchange | NASDAQ |
| Country | NL |
Related companies: ACHV · ALLO · ARCT · CAPR · EDIT · IMMP · MREO
Explore sector: Healthcare · Biotechnology
More sections of PRQR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks